Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)
Tacquell is a tumour-infiltrating lymphocyte therapy for melanoma developed by the Netherlands Cancer Institute, the academic group whose randomised trial first showed TIL therapy could beat ipilimumab. Europe's medicines committee gave it a negative opinion in June 2026, so it is not authorised.
Overview
Tacquell (EMA product number EMEA/H/C/006563; marketing authorisation applicant Netherlands Cancer Institute) is described in the EMA register as autologous melanoma-derived tumour-infiltrating lymphocytes, ex vivo expanded, for the treatment of melanoma. The CHMP adopted its opinion on 25 June 2026 and the opinion status on the product page is negative, so there is no EU marketing authorisation. It is an academic TIL product; the linked key paper is the Netherlands Cancer Institute's randomised phase 3 trial of TIL therapy against ipilimumab (NCT02278887). The only other TIL product with a regulatory history in the corpus is lifileucel (Amtagvi), whose EU application was withdrawn in 2025.
A patient's own tumour-infiltrating lymphocytes are taken from a melanoma deposit, expanded outside the body and returned; the EMA's committee adopted a negative opinion on the application for melanoma (EMA product page).
1.Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes) slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
- 25 Jun 2026Complete response letterEU
CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute source
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tacquell" OR ABSTRACT:"Tacquell" OR TITLE:"autologous melanoma-derived tumour-infiltrating lymphocytes" OR ABSTRACT:"autologous melanoma-derived tumour-infiltrating lymphocytes" OR TITLE:"Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded" OR ABSTRACT:"Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes), not a curated reading list.
Similar pages
not linked directly; found by shared links- PersonInge Marie Svane
Shares Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma, Lifileucel, TIL therapy, Ipilimumab.
- PersonJohn Haanen
Shares Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma, Lifileucel, Netherlands Cancer Institute (NKI-AvL), TIL therapy.
- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Shares Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- TrialC-144-01
Shares Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
- PersonAmod A. Sarnaik
Shares Lifileucel, TIL therapy, Melanoma.
- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Shares Lifileucel, TIL therapy.
- TrialDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Melanoma.